New York, United States:
Johnson & Johnson remains “very confident” in its Covid-19 vaccine and hopeful for a speedy resolution from regulators more than its status, a major executive stated Tuesday.
“We remain very confident and very hopeful that the benefit-risk profile will play out,” J&J Chief Financial Officer Joseph Wolk told CNBC.
The comments came ahead of a selection anticipated later Tuesday from Europe’s drug regulator on the security of the single-shot innoculation.
US pandemic advisor Anthony Fauci stated the United States is most likely to announce its selection by Friday.
Health authorities in the United States on April 14 advised a pause on the vaccine following six situations of serious blood clots out of almost seven million Americans who received the vaccine.
The enterprise hopes “very shortly … perhaps as early as the end of this week, to have some resolution with how we are going to proceed,” Wolk stated.
Asked if the US selection to suspend the system hindered public self-confidence in vaccines, Wolk stated “I would hope that at the end of the week, the population in general will feel more confident in taking the vaccine.”
The comments came as J&J released initial-quarter final results.
An earnings press release did not elaborate on vaccine approval difficulties, but stated the vaccine generated $one hundred million in revenues in the United States throughout the period. J&J is promoting the vaccine at price.
J&J has also encountered production troubles at a Baltimore, Maryland factory managed by Emergent BioSolutions.
The Food and Drug Administration has suspended production in the plant pending a assessment of the facility.
Wolk stated J&J expects to be “in a position to meet our contract commitments, not just here in the US but across the globe” following the FDA assessment.